Liraglutide appears to improve the metabolic profiles of obese type 2 diabetic patients and increase Sirtuin 1(SIRT1) expression, which in turn appears to suppress the pro-inflammatory NF-kB pathway. The gene discussed is SIRT1; the disease is type 2 diabetes mellitus.